Global Health Ebola Update 2/2

EBOLA

Dwindling Patients, Halted Drug Trial
A lack of patients caused a trial of the antiviral drug brincidofovir in Monrovia, Liberia, to be halted late last week.

Chimerix, the drug’s developer, dropped out of the trial which started Jan.2; the company had sent enough supplies to treat 140 patients, but fewer than 10 had been treated. The dwindling number of patients might also slow trials slated to start soon for 2 vaccines and ZMapp.

The Quote: “It’s more important to end the outbreak than to get the trial done,” said Armand Sprecher, a Medecins Sans Frontières public health specialist at one of the brincidofovir trial’s Monrovia treatment sites.
** The New York Times (http://jhsph.us3.list-manage2.com/track/click?u=0a43ad874dbe00d8f0545cfef&id=4b9f95e221&e=9c1fcebfa3)

Related: In pursuit of next-generation Ebola stockpile vaccines – ** Reuters (http://jhsph.us3.list-manage.com/track/click?u=0a43ad874dbe00d8f0545cfef&id=38367a7dec&e=9c1fcebfa3)
** (http://jhsph.us3.list-manage1.com/track/click?u=0a43ad874dbe00d8f0545cfef&id=ba60f46b58&e=9c1fcebfa3)


Related: Ebola likely to persist in 2015 as communities resist aid: Red Cross – ** Reuters (http://jhsph.us3.list-manage.com/track/click?u=0a43ad874dbe00d8f0545cfef&id=72c12f0089&e=9c1fcebfa3)


Related: Sierra Leone's hi-tech weapon against Ebola –
** The Telegraph (UK) (http://jhsph.us3.list-manage.com/track/click?u=0a43ad874dbe00d8f0545cfef&id=62cbb61038&e=9c1fcebfa3)